Clinical Trial Update: [68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer

View source ↗

Summary

Clinical trial update indicates the study of the diagnostic imaging agent 68Ga-PSMA-11 PET/CT for high-risk and recurrent prostate cancer is active but not recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68Ga-PSMA-11 PET/CT (Gallium-68 labeled PSMA-11 radiotracer)

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Prostatic Neoplasm, Prostatic Cancer | Status: ACTIVE_NOT_RECRUITING